HCA SEC Filings

HCA Healthcare, Inc. (HCA) reported strong financial performance for the fiscal year ended December 31, 2025, with revenues increasing to $75.6 billion, a 7.1% rise year-over-year. Net income attributable to HCA Healthcare, Inc. also saw a significant increase, reaching $6.784 billion, up from $5.760 billion in the prior year. This growth was driven by a combination of increased patient volumes, evidenced by a 2.9% rise in equivalent admissions, and an improved revenue per equivalent admission of 4.0%. The company continues to execute its growth strategy, focusing on expanding its presence in existing markets, enhancing operational excellence, and investing in digital and AI capabilities to drive efficiency and improve patient care. Despite a challenging macroeconomic environment marked by inflationary pressures and increasing labor costs, HCA Healthcare demonstrated resilience. The company's strategic investments in its workforce and operational efficiency have helped mitigate some of these pressures. Management remains focused on long-term value creation for stockholders, supported by ongoing share repurchase programs and a consistent dividend. Key risks to monitor include the evolving regulatory landscape, labor market dynamics, and cybersecurity threats, all of which the company actively manages.

HCA Healthcare, Inc. (HCA) filed an 8-K on January 27, 2026, reporting its financial and operational results for the fourth quarter and full year ended December 31, 2025. While the 8-K itself primarily references a press release (Exhibit 99.1) for detailed financial performance, it directly discloses two significant capital allocation decisions by the Board of Directors. These decisions are a substantial $10 billion share repurchase authorization and the declaration of a quarterly cash dividend of $0.78 per share. These announcements indicate a strong focus on returning capital to shareholders. The large share repurchase program suggests management's confidence in the company's valuation and future prospects, potentially signaling a belief that the stock is undervalued. The consistent dividend payment further reinforces a commitment to shareholder returns. Investors will want to closely examine the detailed financial results in the referenced press release to understand the underlying performance driving these capital allocation decisions.

HCA Healthcare, Inc. (HCA) announced the successful completion of a significant public offering of senior notes, raising a total of $3.25 billion. The offering was structured across four tranches with varying maturities and coupon rates: $500 million of 4.300% Senior Notes due 2030, $1 billion of 4.600% Senior Notes due 2032, $1 billion of 4.900% Senior Notes due 2035, and $750 million of 5.700% Senior Notes due 2055. These notes are guaranteed by the parent company, HCA Healthcare, Inc., and represent senior unsecured obligations of the subsidiary issuer. The proceeds from this offering will likely be used to fund general corporate purposes or existing debt refinancing, though specific use of proceeds is not detailed in this filing. The company has also entered into an underwriting agreement with several prominent financial institutions to facilitate this issuance. This move indicates HCA's ongoing strategy to manage its capital structure and potentially fund future growth or operational needs.

HCA Healthcare, Inc. (HCA) reported a strong third quarter of 2025, with revenues increasing by 9.6% to $19.161 billion and net income attributable to HCA Healthcare, Inc. rising by 29.4% to $1.643 billion, or $6.96 per diluted share. This robust performance was driven by a combination of increased patient volumes and higher revenue per equivalent admission. The company has also seen significant improvements in operational efficiencies, particularly in managing labor costs. Despite positive operational results, HCA highlighted several significant policy and economic uncertainties that could impact future performance. These include potential reductions in Medicare reimbursement due to the "One Big Beautiful Bill Act" (OBBBA), the expiration of enhanced premium tax credits (EPTCs) at the end of 2025, ongoing federal government shutdowns, and continued inflationary pressures on operating expenses. HCA is actively engaged in advocacy and implementing resiliency plans to mitigate these potential headwinds. Investors should monitor the evolving regulatory landscape and the company's ability to adapt to these changes.

HCA Healthcare, Inc. (HCA) announced through a press release dated October 27, 2025, the commencement of a proposed public offering of senior unsecured notes by its wholly owned subsidiary, HCA Inc. This offering aims to raise capital, and the specific use of proceeds will be detailed further. Concurrently, HCA Inc. has elected to redeem all of its $1.500 billion of 5.875% senior notes due 2026. This redemption is contingent upon the successful receipt of proceeds from the new note offering and is scheduled for November 26, 2025. This strategic move suggests HCA is likely refinancing existing debt, potentially to lower its interest expenses or extend its maturity profile.

HCA Healthcare, Inc. (HCA) has filed an 8-K report on October 24, 2025, primarily to announce its third-quarter results for the period ending September 30, 2025, via a press release (Exhibit 99.1). While the full financial details are within the press release, this filing serves as official notification of the company's operational and financial performance for the quarter. Investors should refer to the press release for comprehensive information regarding revenue, profitability, and any forward-looking guidance. In addition to the quarterly results, HCA Healthcare announced a quarterly cash dividend of $0.72 per share. This dividend payment, scheduled for December 29, 2025, to stockholders of record on December 15, 2025, demonstrates the company's commitment to returning capital to its shareholders. This dividend declaration is a significant event for income-focused investors.

HCA Healthcare, Inc. reported a strong second quarter for 2025, with consolidated revenues increasing by 6.4% year-over-year to $18.605 billion. This growth was driven by a 3.9% increase in revenue per equivalent admission and a 2.3% rise in equivalent admissions. Net income attributable to HCA Healthcare, Inc. saw a significant jump of 13.1% to $1.653 billion, translating to $6.83 per diluted share, up from $5.53 in the prior year's second quarter. This performance was bolstered by a substantial $2.239 billion increase in cash from operating activities, largely due to favorable working capital changes and a notable decline in income taxes paid thanks to a state tax deferral. The company also continued its share repurchase program, demonstrating a commitment to returning value to shareholders. Despite the positive financial performance, the company faces evolving regulatory landscapes. The recently enacted One Big Beautiful Bill Act (OBBBA) introduces significant changes to Medicaid, potentially impacting patient access and federal health care spending. Additionally, changes to health insurance marketplace rules and the expiration of enhanced premium tax credits could affect payer mix. HCA Healthcare is actively monitoring these developments and implementing resiliency plans. The company's substantial debt load remains a factor, though management believes existing liquidity and access to capital markets are sufficient to meet future needs. Overall, HCA Healthcare delivered robust operational and financial results in the second quarter, while proactively addressing potential regulatory headwinds.

HCA Healthcare, Inc. (HCA) has filed an 8-K report detailing its second quarter 2025 results and announcing a quarterly cash dividend. The press release, attached as Exhibit 99.1, is the primary source of operational and financial information for the quarter ended June 30, 2025. Investors should review this press release for specific financial performance metrics and commentary on the company's condition. In addition to its quarterly results, HCA's Board of Directors has declared a quarterly cash dividend of $0.72 per share. This demonstrates a commitment to returning capital to shareholders and provides income-generating potential for investors holding the stock. The dividend payment is scheduled for September 30, 2025, to shareholders of record on September 16, 2025.

HCA Healthcare, Inc. (HCA) announced a key board change with the appointment of John W. Chidsey, III to its Board of Directors, effective July 15, 2025. This appointment will increase the size of the board from nine to ten members. Mr. Chidsey's addition is intended to bring new perspectives and expertise to the company's governance. Mr. Chidsey has been appointed to serve on three critical board committees: the Audit and Compliance Committee, the Compensation Committee, and the Patient Safety and Quality of Care Committee. His involvement in these committees suggests a focus on financial oversight, executive remuneration, and the company's core operational quality. Investors should note that his appointment is part of the company's established governance framework, with compensation in line with that of other non-management directors.

HCA Healthcare, Inc. (HCA) has announced the establishment of a commercial paper program through its direct, wholly-owned subsidiary, HCA Inc. This program allows for the issuance of unsecured commercial paper notes up to a maximum aggregate principal amount of $4.0 billion outstanding at any time. The Parent Guarantor, HCA Healthcare, Inc., is providing an unconditional guarantee for these notes, indicating strong financial backing for this new financing facility. The primary purpose of this commercial paper program is to provide HCA with flexible access to short-term funding for general corporate purposes. The notes will have maturities of up to 397 days and will be sold on customary terms in the U.S. commercial paper market. Investors should note that this is a private placement and the securities are not registered under the Securities Act of 1933, meaning they are subject to specific exemptions from registration requirements. This move suggests a proactive approach by HCA to manage its liquidity and working capital needs.

HCA Healthcare, Inc. reported solid financial performance for the first quarter of 2025, with revenues increasing by 5.7% year-over-year to $18.321 billion. This growth was driven by a combination of increased equivalent admissions and higher revenue per equivalent admission. Net income attributable to HCA Healthcare, Inc. reached $1.610 billion, or $6.45 per diluted share. While revenue and net income showed positive growth, the company experienced a significant decline in cash flow from operating activities, down $818 million to $1.651 billion, primarily due to negative changes in working capital. The company continues to execute its capital allocation strategy, with substantial share repurchases in the quarter. Management expressed confidence in its ability to meet liquidity needs through operating cash flows, available credit facilities, and access to debt markets, despite a significant debt load of $44.576 billion at the end of the quarter. The report also highlights ongoing risk factors, including inflationary pressures, regulatory changes in healthcare, and the management of substantial indebtedness.

HCA Healthcare, Inc. filed an 8-K on April 28, 2025, detailing key corporate governance updates approved at their Annual Meeting on April 24, 2025. The most significant information for investors pertains to changes in Board of Directors compensation and an expansion of the company's stock incentive plan. The Board approved a new compensation program for non-management directors, which includes revised annual retainers for various committee roles and the Chairmanship, along with a significant annual equity award valued at $220,000 in restricted stock units. This reflects an alignment with attracting and retaining experienced leadership. Furthermore, HCA stockholders overwhelmingly approved an amendment to the 2020 Stock Incentive Plan, increasing the share pool by 13,150,000 shares and extending its term to 2035. This provides the company with substantial equity to incentivize future performance and employee retention. Additionally, an amendment to the Certificate of Incorporation to exculpate officers was approved, offering further protection to management. The filing also confirms the election of all nine director nominees and the ratification of Ernst & Young LLP as the independent auditor.

HCA Healthcare, Inc. (HCA) filed an 8-K on April 25, 2025, primarily to report its first-quarter 2025 financial results, as detailed in an accompanying press release. While the 8-K itself does not provide the specific financial figures, it directs investors to this press release for details on operations and financial condition for the quarter ended March 31, 2025. This filing is crucial for investors seeking to understand the company's recent performance and operational trends. In addition to the financial results announcement, HCA's Board of Directors declared a quarterly cash dividend of $0.72 per share. This dividend, payable on June 30, 2025, to shareholders of record on June 16, 2025, demonstrates a continued commitment to returning capital to shareholders. Investors should review the press release (Exhibit 99.1) for comprehensive details on the company's financial performance and operational highlights for the first quarter.

HCA Healthcare, Inc. (HCA) has filed an 8-K report detailing its 2025 Executive Officer Performance Excellence Program (Executive Officer PEP). This new program outlines the performance-based compensation structure for the company's executive officers, aiming to align their incentives with key financial and operational goals. The program emphasizes achievement of EBITDA targets, which represent 80% of the award opportunity, and quality metrics, accounting for the remaining 20%. This structure suggests a strong focus on profitability and operational efficiency, while also incorporating critical quality of care indicators as defined by the company. For investors, the most significant aspect is the direct link between executive compensation and the achievement of specific financial and quality benchmarks. The program details the potential payout percentages based on performance levels, ranging from threshold to maximum achievement, with specific award opportunities tied to base salary for the CEO, CFO, and COO. The inclusion of stringent conditions, such as a minimum EBITDA performance being required for any quality-based payout, underscores the company's commitment to balancing financial success with patient care excellence. The filing also notes the retirement of a Board member, Meg G. Crofton, effective at the upcoming annual meeting.

HCA Healthcare, Inc. (HCA) has announced the completion of a significant debt offering, raising $5.25 billion in aggregate principal amount of senior notes through its wholly owned subsidiary, HCA Inc. This offering comprises six tranches with varying maturities and interest rates, including senior notes due 2028, 2030, 2032, 2035, and 2055, as well as floating rate senior notes due 2028. These notes are guaranteed on a senior unsecured basis by HCA Healthcare, Inc. and are intended to provide additional financial flexibility for the company. The issuance was completed on February 21, 2025, under the company's existing shelf registration statement and pursuant to multiple supplemental indentures. The specific terms, including interest rates and payment dates, are detailed for each tranche. The notes rank senior to subordinated debt and equally to other senior indebtedness of the Issuer, but are effectively subordinated to secured debt and structurally subordinated to the debt of HCA's subsidiaries. Covenants within the indentures place limitations on liens, sale-leaseback transactions, and asset disposals. Additionally, provisions for optional redemption, change of control triggers with a repurchase price of 101%, and events of default are outlined.

HCA Healthcare, Inc. (HCA) announced through its subsidiary, HCA Inc., the entry into a new, larger senior unsecured revolving credit facility totaling $8.0 billion. This new facility has a five-year term and replaces the company's previous senior secured credit facilities, which included a $3.5 billion revolving credit facility and a $1.238 billion term loan. The company repaid all outstanding obligations under the terminated senior secured facilities immediately prior to entering the new agreement. The refinancing is intended to provide HCA with enhanced financial flexibility for general corporate purposes.

HCA Healthcare, Inc. (HCA) announced on February 18, 2025, the commencement of a proposed public offering of senior unsecured notes by its subsidiary, HCA Inc. This offering is part of a larger "Proposed Refinancing Transaction" aimed at overhauling the company's debt structure. Specifically, HCA intends to use the proceeds from the new notes offering, along with potential borrowings from a new senior unsecured credit facility, to repay and terminate its existing senior secured credit facilities, which include a cash flow credit facility and an ABL credit facility. As of February 14, 2025, HCA Inc. had $2.950 billion outstanding under its ABL credit facility, a portion of which was used to retire $2.600 billion of 5.375% Senior Notes due 2025. The company is also establishing an $8.000 billion senior unsecured credit facility with a five-year term to support general corporate purposes, which may include repaying borrowings from this new facility or the ABL credit facility if the overall refinancing is not fully consummated. This move signifies a strategic shift towards unsecured debt and potentially aims to optimize borrowing costs and financial flexibility.

HCA Healthcare, Inc. reported a robust financial performance for the fiscal year 2024, with revenues reaching $70.6 billion, an increase of 8.7% year-over-year. This growth was driven by a combination of increased patient volumes, as evidenced by a 5.3% rise in equivalent admissions, and a 3.2% increase in revenue per equivalent admission. Net income attributable to HCA Healthcare, Inc. was $5.76 billion, or $22.00 per diluted share, a notable increase from the prior year. The company continued to expand its footprint, operating 190 hospitals and 124 ambulatory surgery centers by year-end. Management highlights strategic investments in clinical systems, digital capabilities, and workforce development as key drivers for sustained growth and operational excellence. Despite strong financial results, HCA faces several risks including significant indebtedness (totaling $43.031 billion), potential labor shortages and associated cost increases, cybersecurity threats, and regulatory changes in the healthcare industry. The company's geographic concentration in Florida and Texas also exposes it to specific regional risks. Management is focused on a disciplined development strategy, enhancing clinical and operational performance, and aligning with value-based care initiatives while navigating these challenges.

HCA Healthcare, Inc. (HCA) has filed an 8-K report on January 24, 2025, detailing significant corporate actions and financial updates. The report primarily announces the company's fourth quarter and full-year 2024 results of operations, which are further elaborated in an accompanying press release (Exhibit 99.1). While specific financial figures from the press release are not detailed in the 8-K text itself, this filing serves as the official notification of these results to the market. Beyond the financial results, HCA has made two key capital allocation announcements. The Board of Directors has authorized a substantial new share repurchase program of up to $10 billion, signaling management's confidence in the company's valuation and commitment to returning capital to shareholders. Additionally, the company declared a quarterly cash dividend of $0.72 per share, reinforcing its consistent return of capital strategy.

HCA Healthcare, Inc. reported a strong third quarter of 2024, with revenues increasing by 7.9% to $17.487 billion and net income attributable to HCA Healthcare, Inc. rising by 17.7% to $1.270 billion ($4.88 per diluted share). This growth was driven by a combination of increased patient volumes, with equivalent admissions up 5.0%, and higher revenue per equivalent admission, up 2.8%. The company also saw a significant improvement in operating cash flow, which increased by $1.036 billion to $3.515 billion for the quarter, primarily due to favorable changes in working capital. Despite facing headwinds such as inflationary pressures on supplies and other operating expenses, and incurring approximately $50 million in losses and additional expenses related to Hurricane Helene, HCA Healthcare demonstrated resilience. The company has proactively managed labor costs, with a notable 17.8% decline in contract labor costs year-over-year. Looking ahead, HCA Healthcare anticipates further impacts from hurricanes Milton and Helene in the fourth quarter, estimated between $200 million and $300 million, but continues its strategic capital allocation through significant share repurchases and dividend payments, signaling confidence in its financial position.

HCA Healthcare, Inc. (HCA) filed an 8-K on October 25, 2024, primarily to furnish its third-quarter 2024 earnings press release. While the 8-K itself does not contain detailed financial figures from the press release, it signals the company's official communication of its operational and financial results for the period ending September 30, 2024. Investors should refer to the accompanying press release (Exhibit 99.1) for specific revenue, profit, and operational metrics. In addition to the financial results announcement, HCA's Board of Directors declared a quarterly cash dividend of $0.66 per share. This dividend is payable on December 27, 2024, to shareholders of record as of December 13, 2024. This action indicates continued capital return to shareholders and should be considered by income-focused investors.

HCA Healthcare, Inc. (HCA) has filed an 8-K report on August 12, 2024, detailing the completion of a significant public offering of senior notes totaling $3,000,000,000 in aggregate principal amount. This offering consists of three tranches: $750,000,000 of 5.450% Senior Notes due 2031 (New 2031 Notes), $1,250,000,000 of 5.450% Senior Notes due 2034 (2034 Notes), and $1,000,000,000 of 5.950% Senior Notes due 2054 (2054 Notes). These notes are senior unsecured obligations of HCA Inc., guaranteed on a senior unsecured basis by the Parent Guarantor, HCA Healthcare, Inc. The issuance of these notes is a material event for investors as it impacts the company's capital structure and long-term financing. The proceeds from this offering will be used to refinance existing debt and for general corporate purposes, though specific use of proceeds beyond that is not detailed in this filing. The tiered interest rates and maturity dates reflect market conditions and the company's debt management strategy. Investors should note the covenants and change of control provisions detailed in the Indentures, which offer certain protections.

HCA Healthcare, Inc. (HCA) announced on August 7, 2024, through an 8-K filing, that it has entered into an Underwriting Agreement to issue and sell $3.0 billion in aggregate principal amount of senior notes. This debt offering consists of three tranches: $750 million of 5.450% Senior Notes due 2031, $1.25 billion of 5.450% Senior Notes due 2034, and $1.0 billion of 5.950% Senior Notes due 2054. These notes will be guaranteed on a senior unsecured basis by the Parent Guarantor, HCA Healthcare, Inc., and are being issued under the company's existing Form S-3 registration statement.

HCA Healthcare, Inc. (HCA) reported strong financial results for the second quarter of 2024, showcasing significant year-over-year growth in both revenue and net income. Total revenues reached $17.492 billion, a 10.3% increase compared to the same period last year, driven by a healthy rise in revenue per equivalent admission and overall equivalent admissions. Net income attributable to HCA Healthcare, Inc. saw a substantial increase to $1.461 billion, translating to $5.53 per diluted share, up from $1.193 billion or $4.29 per diluted share in Q2 2023. This performance was bolstered by increased patient volumes, with a notable rise in admissions and emergency department visits, while surgeries saw a slight decline. Despite the robust revenue and profit growth, the company experienced a decline in cash flow from operating activities, primarily due to negative changes in working capital and higher income tax payments. However, HCA Healthcare maintained a strategic approach to capital allocation, repurchasing a significant amount of its common stock and continuing its dividend program. The company also highlighted its ongoing investments in capital expenditures, projecting between $5.1 billion and $5.3 billion for 2024, underscoring its commitment to facility improvements and expansion. Management expressed confidence in its ability to meet future liquidity needs through operating cash flows, credit facilities, and access to debt markets, while acknowledging persistent inflationary pressures on operating expenses.

HCA Healthcare, Inc. (HCA) filed an 8-K on July 23, 2024, primarily to disclose its second-quarter 2024 financial results via a press release. While the specific financial figures are detailed within the attached press release (Exhibit 99.1), the filing itself confirms the company is communicating its operational performance for the period ended June 30, 2024. In addition to the quarterly results, HCA Healthcare also announced a quarterly cash dividend of $0.66 per share. This dividend underscores the company's commitment to returning capital to shareholders and provides a concrete return for investors. The payment date is set for September 30, 2024, with a record date of September 16, 2024, offering investors a clear timeline for dividend receipt.

HCA Healthcare, Inc. reported strong financial performance for the first quarter of 2024, with revenues increasing by 11.2% year-over-year to $17.339 billion. This growth was driven by a 7.1% increase in equivalent admissions and a 3.9% rise in revenue per equivalent admission, indicating robust patient volume and effective pricing strategies. Net income attributable to HCA Healthcare, Inc. rose by 16.7% to $1.591 billion, or $5.93 per diluted share, demonstrating improved profitability. The company also reported a significant increase in cash flow from operations, which grew by $666 million to $2.469 billion, primarily due to favorable working capital changes and higher net income. Despite significant planned capital expenditures of $5.1 billion to $5.3 billion for 2024, HCA Healthcare maintains a solid liquidity position, with substantial amounts available under its senior secured credit facilities. The company continued its commitment to shareholder returns through active share repurchases and dividend payments.

HCA Healthcare, Inc. (HCA) filed an 8-K report on April 29, 2024, detailing key events from its Annual Meeting of Stockholders held on April 25, 2024, and a CFO transition. The report announced the retirement of Executive Vice President and CFO William B. Rutherford, effective May 1, 2024, with Christopher F. Wyatt appointed as the new principal accounting officer while continuing his role as Senior Vice President and Controller. This transition appears smooth with no immediate concerns indicated regarding Mr. Wyatt's appointment. The Annual Meeting saw strong stockholder support for the re-election of all ten director nominees and the ratification of Ernst & Young LLP as the independent registered public accounting firm. Furthermore, stockholders approved a non-binding advisory resolution to hold annual say-on-pay votes, aligning with the board's determination to conduct these votes yearly. Conversely, several stockholder proposals concerning risk mitigation for state restrictions on emergency abortions, patient feedback on care quality, and maternal health outcomes were not approved.

HCA Healthcare, Inc. (HCA) filed an 8-K on April 26, 2024, primarily announcing its first quarter 2024 financial results via a press release. While specific financial figures are detailed in the referenced Exhibit 99.1, the filing itself serves as notification of these results. Investors should refer to the attached press release for comprehensive details on revenue, profitability, and operational performance during the quarter ended March 31, 2024. Additionally, the Company announced a quarterly cash dividend of $0.66 per share, payable on June 28, 2024, to shareholders of record on June 14, 2024. This dividend declaration underscores HCA's commitment to returning capital to its shareholders and provides a direct financial benefit to investors holding the stock.

HCA Healthcare, Inc. (HCA) filed an 8-K on February 26, 2024, detailing its 2024 Executive Officer Performance Excellence Program (Executive Officer PEP). This program establishes performance-based compensation for the company's executive officers, with awards weighted 80% on EBITDA targets and 20% on quality metrics. Specific EBITDA targets will be set for the company overall and for key operating groups, while quality metrics will focus on Healthcare-Associated Infections and Sepsis, Complication and Mortality, and Care Experience. Furthermore, the filing announces an adjustment to the compensation for Michael R. McAlevey, who will transition to Executive Vice President – Chief Legal and Administrative Officer on April 1, 2024. This transition includes a base salary increase and a significant long-term equity incentive award. Notably, William B. Rutherford, Executive Vice President and Chief Financial Officer, will retire on May 1, 2024, and will not participate in the Executive Officer PEP.

This 8-K/A filing from HCA Healthcare, Inc. serves as an amendment to a previous 8-K announcing the appointment of Michael A. Marks as Executive Vice President and Chief Financial Officer, effective May 1, 2024. The primary purpose of this amendment is to disclose material changes to Mr. Marks' compensation arrangements related to his new role, which were not finalized at the time of the initial filing. Key details of the compensation changes include the establishment of the 2024 Executive Officer Performance Excellence Program (Executive Officer PEP). Under this program, Mr. Marks' performance awards will be weighted 80% towards EBITDA targets and 20% towards specific quality metrics. These quality metrics encompass Healthcare-Associated Infections and Sepsis, Complication and Mortality, and Care Experience. His award opportunity will increase from 65% of base salary to 110% of base salary upon assuming the CFO role.

HCA Healthcare, Inc. (HCA) has filed an 8-K report detailing a significant financing transaction. On February 23, 2024, the company, through its subsidiary HCA Inc., successfully completed the public offering of $4.5 billion in aggregate principal amount of senior unsecured notes. These notes are structured across various maturity dates and interest rates, including $1.0 billion of 5.450% notes due 2031, $1.3 billion of 5.600% notes due 2034, $1.5 billion of 6.000% notes due 2054, and $0.7 billion of 6.100% notes due 2064. The parent company, HCA Healthcare, Inc., fully and unconditionally guarantees these notes. This substantial debt issuance, registered under a Form S-3 shelf registration statement, provides HCA with significant capital. The proceeds are intended to fund general corporate purposes, which may include capital expenditures, debt repayment, or acquisitions, although specific use of proceeds is not detailed in this filing. The indenture governing these notes includes standard covenants related to liens, sale and lease-back transactions, and asset disposals, as well as provisions for optional redemption and a change of control repurchase right for noteholders under specific conditions. Investors should note that while these notes are senior unsecured obligations of the issuer, they are effectively subordinated to secured debt and structurally subordinated to the debt and liabilities of HCA's subsidiaries.

HCA Healthcare, Inc. (HCA) announced on February 20, 2024, the execution of an underwriting agreement for the issuance and sale of $4.5 billion in aggregate principal amount of senior notes. This significant debt financing is structured across four tranches with varying maturity dates and interest rates, ranging from 5.450% due in 2031 to 6.100% due in 2064. The notes will be guaranteed on a senior unsecured basis by the parent company, HCA Healthcare, Inc., and are being issued under the company's existing Form S-3 registration statement. This debt offering is a material event for investors as it provides insight into HCA's capital structure management and financing strategy. The substantial capital raised may be intended for various corporate purposes, such as funding operations, acquisitions, refinancing existing debt, or general corporate expenditures. Investors should monitor how these funds are deployed and assess the impact on the company's leverage ratios and overall financial health. The specific terms of the notes, including their coupon rates and maturity profiles, reflect current market conditions and HCA's credit standing.

HCA Healthcare, Inc. (HCA) reported robust revenue growth in its 2023 annual report, with total revenues reaching $64.968 billion, a 7.9% increase over 2022. This growth was primarily driven by a 4.9% rise in equivalent admissions and a 2.8% increase in revenue per equivalent admission. Despite this top-line expansion, net income attributable to HCA Healthcare decreased to $5.242 billion from $5.643 billion in the prior year, impacted by the absence of significant facility sale gains recorded in 2022 and increased operating expenses, particularly in 'other operating expenses' which rose as a percentage of revenue. The company continues to invest heavily in its operations, with capital expenditures reaching $4.744 billion (excluding acquisitions) in 2023, indicating a commitment to enhancing facilities and services. HCA also returned significant capital to shareholders through share repurchases totaling $3.811 billion and dividends of $661 million in 2023. The company's strategic focus remains on expanding its presence in existing markets, achieving operational excellence, and recruiting top talent, positioning it for continued growth despite a competitive landscape and ongoing healthcare industry reforms.

HCA Healthcare, Inc. (HCA) filed an 8-K on January 30, 2024, reporting key financial and operational updates. The company announced its financial results for the fourth quarter and full year ended December 31, 2023, via a press release. Additionally, the filing disclosed significant leadership changes, including the retirement of Executive Vice President and Chief Financial Officer William B. Rutherford, effective May 1, 2024. Michael A. Marks, a long-time HCA employee with extensive finance experience within the company, has been appointed to succeed Mr. Rutherford, also effective May 1, 2024. In addition to personnel updates, HCA announced a substantial $6 billion share repurchase program authorization from its Board of Directors, signaling a commitment to returning capital to shareholders. The company also declared its quarterly cash dividend of $0.66 per share. These announcements collectively highlight HCA's financial performance, strategic capital allocation, and leadership transition.

HCA Healthcare, Inc. (HCA) filed an 8-K on November 9, 2023, to disclose preliminary financial outlook and long-term targets in advance of their Investor Day. This early perspective aims to provide stakeholders with forward-looking insights into the company's strategic direction and growth potential. Investors should note that the information provided is intended to be a preview and further details will be discussed during the upcoming Investor Day presentations. The company also announced plans to webcast its Investor Day presentations and Q&A session, with materials to be made available on their Investor Relations website. This proactive communication strategy underscores HCA's commitment to transparency and engaging with its investor base on future financial objectives and operational strategies.

HCA Healthcare, Inc. (HCA) reported strong revenue growth in its third quarter of 2023, with total revenues reaching $16.213 billion, an increase of 8.3% year-over-year. This growth was driven by a combination of increased revenue per equivalent admission (up 3.6%) and higher equivalent admissions (up 4.5%). While revenue demonstrated robust performance, net income attributable to HCA Healthcare, Inc. saw a slight decrease to $1.079 billion ($3.91 per diluted share) from $1.134 billion ($3.91 per diluted share) in the prior year's quarter. This was partially influenced by a $105 million pre-tax loss related to a recently acquired hospital-based physician staffing joint venture. The company experienced an increase in patient volumes across key areas, with consolidated admissions up 2.8% and same-facility admissions up 3.4%. Emergency department visits and surgeries also saw modest increases. Despite the revenue growth, operating cash flow declined by $541 million to $2.479 billion, primarily due to unfavorable changes in working capital. Management anticipates continued inflationary pressures impacting operating expenses and maintains sufficient liquidity through operating cash flows, credit facilities, and access to debt markets.

HCA Healthcare, Inc. (HCA) filed an 8-K on October 24, 2023, primarily to announce its third-quarter 2023 financial results via an attached press release (Exhibit 99.1). While the 8-K itself does not contain detailed financial figures, it directs investors to the press release for operational and financial performance. This filing is crucial for investors seeking the latest financial updates and performance indicators from HCA, including revenue, earnings, and operational metrics for the most recent quarter. Additionally, the filing disclosed that HCA's Board of Directors declared a quarterly cash dividend of $0.60 per share, payable on December 28, 2023, to shareholders of record as of December 14, 2023. This dividend declaration signals the company's continued commitment to returning capital to its shareholders and provides a concrete income stream for investors.

HCA Healthcare, Inc. reported a solid second quarter for 2023, with revenues increasing by 7.0% to $15.861 billion compared to the same period in 2022. Net income attributable to HCA Healthcare, Inc. also saw a modest increase, reaching $1.193 billion, or $4.29 per diluted share. This growth was driven by a combination of increased patient volumes, evidenced by a 4.0% rise in equivalent admissions, and a 2.9% increase in revenue per equivalent admission. The company continues to manage its cost structure effectively, with salaries and benefits remaining relatively stable as a percentage of revenue, though other operating expenses, particularly professional fees, saw an increase. Cash flows from operations showed significant strength, increasing by $845 million year-over-year, largely due to positive changes in working capital. Despite economic uncertainties and inflationary pressures, HCA demonstrated resilience. The company experienced a decline in uninsured admissions, which is a positive sign for revenue collection. Management expects to fund significant capital expenditures, projected at $4.7 billion for 2023, through a combination of operational cash flow and debt. A notable event during the quarter was a data security incident announced in July 2023, involving patient information for approximately 11 million individuals. While the investigation is ongoing, HCA stated it does not believe this incident will materially impact its business or financial results.

HCA Healthcare, Inc. (HCA) filed an 8-K on July 27, 2023, primarily to announce its financial results for the second quarter ended June 30, 2023, via a press release. While the specific financial metrics are detailed within the attached press release (Exhibit 99.1), this filing signals that the company is providing an update on its operational and financial performance for the most recent quarter. In addition to the quarterly results, HCA announced a quarterly cash dividend of $0.60 per share. This dividend, payable on September 29, 2023, to shareholders of record on September 15, 2023, demonstrates the company's commitment to returning capital to its shareholders. Investors should review the associated press release for comprehensive details on revenue, profitability, and any forward-looking guidance provided by HCA.

HCA Healthcare, Inc. (HCA) has filed an 8-K report on July 10, 2023, to disclose a significant data security incident. The company announced that a portion of its data, including patient information, was accessed and exfiltrated by an unauthorized third party. While HCA states it is still investigating the full scope of the incident, the preliminary assessment suggests that the accessed data included patient names, contact information, dates of birth, and potentially clinical information and social security numbers for a subset of patients. The company is working with external cybersecurity experts and has notified law enforcement.

HCA Healthcare, Inc. (HCA) has filed a Current Report on Form 8-K to disclose a reorganization of its operating segments. Effective January 1, 2023, the company transitioned from two geographically organized groups to three: the National, American, and Atlantic Groups. This report retrospectively revises the historical segment reporting financial information previously presented in the Company's Annual Report on Form 10-K for the year ended December 31, 2022. Investors should note that this filing does not restate or reclassify HCA's previously reported consolidated financial statements for any period. The purpose of this 8-K is solely to align historical segment data with the new operational structure. All other information within the 2022 Form 10-K remains unchanged. The revised segment information is provided in Exhibit 99.1.

HCA Healthcare, Inc. (HCA) announced the completion of a significant public offering of senior unsecured notes totaling $3.25 billion on May 4, 2023. This offering comprises three tranches: $1 billion in 5.200% Senior Notes due 2028, $1.25 billion in 5.500% Senior Notes due 2033, and $1 billion in 5.900% Senior Notes due 2053. These notes are issued by HCA Inc., a wholly owned subsidiary, and are guaranteed on a senior unsecured basis by the parent company, HCA Healthcare, Inc. The proceeds from this issuance are intended to fund general corporate purposes. This move diversifies HCA's debt maturity profile and provides substantial capital. From an investor's perspective, this filing indicates the company's proactive management of its capital structure and its ability to access public debt markets efficiently. The guaranteed nature of the notes by the parent company offers a strong layer of credit support. While the new debt increases HCA's overall leverage, the company has outlined standard covenants that aim to protect noteholders, including restrictions on liens, sale-leaseback transactions, and asset disposals. The inclusion of a change of control provision with a premium repurchase price for noteholders also provides a measure of protection against significant unfavorable corporate events.

HCA Healthcare, Inc. (HCA) has filed an 8-K report detailing a significant debt issuance. On May 1, 2023, the company, through its wholly-owned subsidiary HCA Inc., entered into an underwriting agreement to issue and sell $3.25 billion in senior notes. This offering is comprised of three tranches: $1 billion of 5.200% Senior Notes due 2028, $1.25 billion of 5.500% Senior Notes due 2033, and $1 billion of 5.900% Senior Notes due 2053. The Notes will be senior unsecured obligations, guaranteed by HCA Healthcare, Inc. The issuance is being conducted under the company's effective registration statement on Form S-3. This action signals a strategic move by HCA to raise substantial capital, likely to fund ongoing operations, potential acquisitions, or refinance existing debt under potentially more favorable terms. Investors should note the varying interest rates and maturity dates across the different tranches.

HCA Healthcare, Inc. reported solid financial results for the first quarter of 2023, demonstrating revenue growth and improved profitability. Total revenues increased by 4.3% to $15.591 billion compared to the prior year, driven by a significant increase in equivalent admissions. Net income attributable to HCA Healthcare, Inc. also saw a healthy rise of 7.1% to $1.363 billion, resulting in earnings per diluted share of $4.85. The company's operational performance was characterized by a notable increase in patient volumes, with equivalent admissions up 6.7% and same-facility admissions rising by 4.4%. This growth was supported by a higher volume of surgeries and emergency department visits. While revenue per equivalent admission experienced a slight decline, this was largely attributed to the comparison with a prior year period that included higher COVID-19 volumes and reimbursement. From a financial health perspective, cash flow from operations significantly improved, increasing by $458 million to $1.803 billion, driven by both increased net income and favorable changes in working capital. Despite a robust increase in capital expenditures to support facility improvements and expansion, the company maintained its liquidity. HCA Healthcare also continued its commitment to shareholder returns through share repurchases and dividend declarations.

HCA Healthcare, Inc. (HCA) filed an 8-K on April 21, 2023, reporting the results of its Annual Meeting of Stockholders held on April 19, 2023. The primary focus of this filing is the outcome of various shareholder votes, including the election of directors, ratification of auditors, and approval of corporate plans. Notably, all ten director nominees were elected with substantial support, indicating shareholder confidence in the current leadership. The company's 2023 Employee Stock Purchase Plan also received strong approval from stockholders, signaling support for employee ownership and engagement initiatives. The filing also confirms the ratification of Ernst & Young LLP as the independent registered public accounting firm for the upcoming fiscal year, a standard but crucial vote for financial oversight. Additionally, shareholders approved an advisory resolution on executive compensation, reflecting general satisfaction with the company's compensation practices. Conversely, two shareholder proposals, one concerning political spending disclosure and another regarding an amendment to the Patient Safety and Quality of Care Committee charter, did not receive majority approval.

HCA Healthcare, Inc. (HCA) filed an 8-K on April 21, 2023, primarily to announce its first-quarter 2023 financial results and a quarterly dividend. The company reported its operational and financial condition for the period ending March 31, 2023. This filing serves as a key update for investors regarding the company's performance and capital return strategy. In addition to the financial results, HCA's Board of Directors declared a quarterly cash dividend of $0.60 per share. This demonstrates a commitment to returning value to shareholders and provides a concrete return for the current quarter, payable on June 30, 2023. Investors should refer to the press release filed as Exhibit 99.1 for detailed financial information.

HCA Healthcare, Inc. (HCA) has filed an 8-K detailing its new 2023 Senior Officer Performance Excellence Program (Senior Officer PEP). This program outlines the incentive compensation structure for the company's executive officers, with awards weighted 80% towards EBITDA targets and 20% towards quality metrics. The program aims to align executive compensation with both financial performance and patient care quality. Key features include tiered payout structures for performance against targets, with specific award opportunities outlined for the CEO, CFO, COO, and Chief Legal Officer, expressed as percentages of their base salaries. The program also includes provisions for adjustments, clawbacks in certain circumstances, and is payable in cash. Investors should note the emphasis on EBITDA and specific quality indicators, which provides insight into HCA's strategic priorities for executive performance in 2023.

HCA Healthcare, Inc. reported revenues of $60.233 billion for the year ended December 31, 2022, a 2.5% increase from 2021. Net income attributable to HCA Healthcare, Inc. was $5.643 billion, or $19.15 per diluted share, a decrease from $6.956 billion in 2021, primarily due to gains on sales of facilities in prior periods. The company experienced growth in key operational metrics such as emergency room visits and outpatient surgeries on a consolidated and same-facility basis. The company continues to manage its significant debt load, which stood at $38.084 billion as of December 31, 2022. HCA Healthcare remains focused on its growth strategy, including expanding its presence in existing markets, operational excellence, and strategic investments in clinical systems and digital capabilities. Key risk factors continue to include the impact of COVID-19, labor costs, regulatory changes, and competition within the healthcare industry.

This 8-K Amendment from HCA Healthcare, Inc. (HCA) provides crucial updates on the compensation package for its newly appointed Executive Vice President and Chief Operating Officer, Jon M. Foster. While the initial appointment was announced in October 2022, this filing details material changes to Mr. Foster's compensation, approved by the Compensation Committee in January 2023. The key changes include an increase in base salary and a significant long-term equity incentive award, signaling the company's investment in key executive talent for its operational leadership. Investors should note the details of Mr. Foster's enhanced compensation, which includes a base salary adjustment to $1,000,000 and a substantial equity grant valued at $3,750,000. This equity award is structured with a mix of stock appreciation rights and performance share units, aligning a significant portion of his compensation with long-term company performance and shareholder value. This filing clarifies compensation details that were undetermined at the time of the initial appointment announcement.

HCA Healthcare, Inc. (HCA) filed an 8-K on January 27, 2023, primarily to announce its financial results for the fourth quarter and full year ended December 31, 2022, as detailed in an accompanying press release (Exhibit 99.1). While the 8-K itself doesn't provide the granular financial figures, it signifies the official release of this operational and financial data, which investors should review in the linked press release for a comprehensive understanding of the company's performance during the reported periods. In addition to financial results, the filing disclosed significant capital allocation decisions by HCA's Board of Directors. The company announced an authorization of a new share repurchase program, allowing for up to $3 billion in stock buybacks, signaling management's confidence in the company's valuation and a commitment to returning capital to shareholders. Furthermore, HCA declared a quarterly cash dividend of $0.60 per share, reinforcing its policy of providing consistent income to its investors.